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DECREASED ECTO-NTPDASE1/CD39 ACTIVITY LEADS TO
DESENSITIZATION OF P2 PURINOCEPTORS REGULATING
TONUS OF CORPORA CAVERNOSA IN IMPOTENT MEN WITH
ENDOTHELIAL DYSFUNCTION
M. Faria,1 T. Magalha˜es-Cardoso,1 J.-M. Lafuente-de-Carvalho,2
and P. Correia-de Sa´1
1Laborato´rio de Farmacologia e Neurobiologia/UMIB, Instituto de Cieˆncias Biome´dicas Abel
Salazar–Universidade do Porto (ICBAS-UP), Porto, Poturgal
2Servic¸o de Urologia, Hospital Geral de Santo Anto´nio (HGSA), Porto, Portugal
 Vascular responses to adenine nucleotides in human corpora cavernosa from men with vas-
culogenic erectile dysfunction were investigated. We also evaluated the catabolism of extracellular
adenine nucleotides to probe its relevance to vascular hemodynamics in impotent men. Human cor-
pora cavernosa have high NTPDase1/CD39 activity, converting ATP directly into AMP, without
significant ADP formation. Extracellular ATP hydrolysis is slower in impotent patients. Adenine
nucleotides have dual roles on phenylephrine-contracted strips of corpora cavernosa operated by
P2X-contractant and P2Y-relaxant receptors. Prolonged exposure to endogenous ATP related to de-
creased NTPDase1/CD39 activity leads to P2-purinoceptor desensitization in impotent men. Shut-
ting down ATP signaling in vasculogenic impotent men may represent a defense mechanism for
preventing purinergic overstimulation.
Keywords Erectile dysfunction; human corpus cavernosum; P2 purinoceptors; ectonu-
cleotidases; ecto-NTPDase1/CD39; adenine nucleotides
INTRODUCTION
Purinergic transmission is important for initiation and maintenance
of penile erection.[1] ATP released by blood elements, endothelium, and
smooth muscle is a powerful regulator of vascular hemodynamics. In most
vascular beds, ATP acts via P2X receptors located on vascular smooth mus-
cle cells to mediate vasoconstriction. Alternatively, adenine nucleotides
may cause vasodilatation either directly, through P2Y receptors located on
endothelium and smooth muscle fibres, or indirectly, via adenosine gener-
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SFRH/BD/25470/2005) and Sociedade Portuguesa de Andrologia (SPA).
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ated by ecto-nucleotidases. We recently demonstrated that adenosine regu-
lates human corpus cavernosum (HCC) tone via CGS21680C-sensitive (A2A)
and -insensitive (A2B) receptors located on smooth muscle and endothelial
cells, respectively.[2] Because the functional significance of P2 purinoceptors
in erectile tissue remains unclear, we investigated the vascular responses of
HCC from control subjects and from impotent men with endothelial dys-
function to two subtype-selective P2-receptor agonists, α,β-methylene ATP
(α,β-MeATP), and ATPγ S.
The biological effects of adenine nucleotides may be cut-short by
extracellular hydrolysis via the ecto-nucleotidase cascade. Many of the
ecto-nucleotidases catalytically remove nucleotides in tandem with other
ecto-enzymes to generate nucleosides at very high turnover rates. CD39,
an apyrase or ecto-nucleoside triphosphate diphosphohydrolase (ecto-
NTPDase 1), was identified as the first member of the ecto-nucleotidase
family and its main function is to hydrolyse nucleoside tri- and diphosphates
yielding monophosphates of both purine and pyrimidine nucleosides.[3]
Ecto-NTPDase 1/CD39 is a plasma membrane-bound enzyme highly ex-
pressed in the vasculature (endothelium, smooth muscle, and cardiac cells),
lymphocytes and platelets.[4] Transgenic mice with targeted disruption of
ecto-NTPDase 1/CD39 exhibit alterations in hemostasis and in inflamma-
tory and thrombotic reactions to reperfusion injury.[5]
Endothelial dysfunction is a cornerstone in the pathophysiology of both
erectile dysfunction (ED) and cardiovascular diseases, with the two entities
sharing a high degree of interdependence concerning severity.[6] We have
demonstrated that endothelial dysfunction is correlated with a loss of adeno-
sine A2B receptor activity in penile vessels from men with vasculogenic ED.[2]
Evidence that endothelial cell dysfunction may also be correlated with the
loss of ecto-NTPDase 1/CD39 activity,[7] prompted us to investigate the pat-
tern of extracellular catabolism of adenine nucleotides to probe its rele-
vance to purinergic signaling in vasculogenic ED patients.
MATERIAL AND METHODS
Human Corpus Cavernosum (HCC) Tissues
HCC specimens were obtained from control subjects (bodies donated
for harvesting organs, 18–50 years) and from patients suffering from vascu-
logenic ED (48–58 years) at the time of penile prosthesis insertion. All the
patients were informed of procedures and signed their written consent. The
protocol was approved by the Ethics Committee of HGSA (University Hos-
pital) and of ICBAS (Medical School) of the University of Porto. The inves-
tigation conforms to the principles outlined in the Declaration of Helsinki.
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Isometric Tension Assay
Longitudinal strips of corpus cavernosum tissue (3 × 3 × 7 mm) were
mounted in 12 ml organ chambers containing oxygenated (95% O2/5%
CO2, pH 7.4) Tyrode’s solution (composition in mM: NaCl 137, KCl 2.7,
CaCl2 1.8, MgCl2 1, NaH2PO4 0.4, NaHCO3 11.9, glucose 11.2, and ascorbic
acid, 100) at 37◦ C. HCC strips were connected to isometric force transduc-
ers, and changes in tension were recorded continuously with a PowerLab
data acquisition system (Chart 5, v.4.2; AD Instruments, Colorado Springs,
CO, USA). Tissues were preloaded with 2 g of tension and allowed to equi-
librate for 90 minutes in Tyrode’s solution. Each strip was incrementally
stretched to optimal isometric tension, as determined by maximal contrac-
tile response to 1 µM phenylephrine (PE). After standardization, relaxation
to acetylcholine (ACh, 1–10 µM) was taken as a measure of endothelium
integrity. To evaluate tissue relaxant responsiveness, HCC strips were con-
tracted with 1 µM PE, and once a stable contraction was achieved (15–20
minutes) the strips were challenged with cumulative additions of ATPγ S
and α,β-MeATP to the chambers.
Extracellular Metabolism of Adenine Nucleotides
To study the kinetics of ATP and AMP inactivation in HCC taken from
control subjects and from patients with vasculogenic ED, longitudinal strips
(3 × 3 × 7 mm) were mounted in 1.5 ml organ baths containing oxygenated
(95% O2/5% CO2, pH 7.4) Tyrode’s solution at 37◦C. After a 30 minutes
equilibration period, the preparations were incubated with 30 µM ATP or
AMP (zero time). Samples of 75 µl were collected from the organ bath at
different times up to 45 min for HPLC (L-6200 intelligent pump with a
L-4000 UV detector, Hitachi, Germany) analysis of the variation of substrate
disappearance and product formation.[8]
Presentation of Data and Statistical Analysis
The data are expressed as mean ± S.E.M. from n number of individu-
als, and at least four strips were used for each experiment. The responses
are expressed as percentage of PE (1 µM) contractions. For multiple com-
parisons, results were analyzed by analysis of variance (ANOVA) followed by
the Bonferroni’s posttest. For comparison between two values, the unpaired
Student’s t -test was used. A value of P < 0.05 was considered significant.
RESULTS
HCC from control subjects hydrolyzes extracellular ATP (30 µM) with
a half-degradation time of 9 ± 2 minutes (n = 4) (Table 1). The ATP
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TABLE 1 Half-degradation time of ATP (30 µM) on HCC strips from control subjects and from
vasculogenic impotent men with endothelial dysfunction
Control individuals Vasculogenic ED patients
ATP catabolism (t1/2, minute) 9 ± 2 (4) 26 ± 1 (3)*
ACh (1 µM) relaxation (% of maximal contraction) 23 ± 4% (21) 73 ± 7% (11)*
Half-degradation time (t1/2, minute, ± S.E.M.) of extracellular ATP (30 µM) inactivation in HCC
strips obtained from control subjects and from patients with vasculogenic ED. Relaxation to 1 µM ACh
was taken as measure of endothelium integrity; values are expressed as a percentage (±S.E.M.) of max-
imal contraction caused by 1 µM PE. The number of individual human specimens is shown between
parentheses.
*P < 0.05 as compared with data obtained in control individuals.
metabolites detected in the bath were AMP, whose accumulation was de-
tected within the first min and reached a maximum of 6.8 ± 1.5 µM at 15
minutes, adenosine, whose maximum concentration (22.1 ± 3.8 µM) was
reached at 45 minutes, and inosine, whose maximum concentration (8.9
± 0.7 µM) was also reached at 45 minutes. Surprisingly, small amounts
of ADP (<1.5 µM) were detected only after a 5-minute incubation pe-
riod. This pattern of extacellular catabolism of ATP suggests the pres-
ence of ecto-NTPDase 1/CD39 enzyme converting ATP directly into AMP,
which is then sequentially inactivated into adenosine and inosine by ecto-5’-
nucleotidase (CD73) and ecto-adenosine deaminase, respectively (see, e.g.,
Faria et al.[2]). Table 1 shows that the extracellular catabolism of ATP is sig-
nificantly (P < 0.05) slower in HCC from vasculogenic ED patients (t1/2 =
26 ± 1 minute; n = 3) than in control subjects. The rate of AMP (30 µM)
metabolism was similar when comparing the two groups of samples (data
not shown).
Endothelial dysfunction of HCC strips isolated from vasculogenic ED
patients was confirmed in vitro by a significant (P < 0.05) reduction of ACh
(1 µM)-induced relaxation (Table 1). The two metabolically stable adenine
nucleotides exerted a dual role on HCC strips pre-contracted with 1 µM
PE. The P2X agonist, α,β-MeATP (0.3–30 µM), transiently increased the
HCC tonus in a concentration-dependent manner (Figure 1); when ap-
plied in concentrations higher than 100 µM, α,β-MeATP also increased
HCC tonus but the increase was smaller than that observed with 30 µM
(32 ± 3%, n = 3). Contractile responses to α,β-MeATP (0.3–300 µM) were
sensitive to blockade with pyridoxal phosphate-6-azophenyl-2’,4’-disulfonic
acid (PPADS, 10 µM) and were significantly (P < 0.05) attenuated in vas-
culogenic ED patients; this compound failed to increase HCC tension be-
yond 16 ± 2% (n = 3), even when a higher concentration (100 µM) was
used. The nonselective P2 purinoceptor agonist, ATPγ S (1–100 µM), had
a biphasic effect on HCC tonus in control individuals (Figure 2). ATPγ S
(1–100 µM) transiently increased HCC tension, which was then followed by
a concentration-dependent relaxing effect (IC25 = 10 µM). At the highest
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FIGURE 1 Contractile responses of pre-contracted (with 1 µM PE) HCC strips from control subjects and
from patients with vasculogenic ED to α,β-MeATP (0.3–300 µM). Shown are typical recording traces of
increased HCC tension by cumulative application of α,β-MeATP (0.3–300 µM).
concentration (100 µM) tested, ATPγ S caused only a mild relaxing effect of
23 ± 6% (n = 5) in patients with vasculogenic ED. Pyrimidine nucleotides
(such as UTP and UDP) were virtually devoid of effect on HCC tension (data
not shown). Overall these results indicate that both P2X- and pyrimidine-
insensitive P2Y-mediated responses of HCC from men with vasculogenic ED
are markedly depressed.
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FIGURE 2 Biphasic responses of pre-contracted (with 1 µM PE) HCC strips from control subjects and
from patients with vasculogenic ED to ATPγ S (1–100 µM). Shown are typical recording traces of tension
changes induced by cumulative application of ATPγ S (1–100 µM) on HCC strips. Horizontal dashed
lines are shown to facilitate distinction between transient increases in tension and the following relaxant
component for a given drug concentration.
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DISCUSSION
The concentration of extracellular nucleotides is regulated by a variety
of surface-located enzymes known as ecto-nuclotidases; most of them are
members of the ecto-NTPDase family.[3,9] The most widely expressed NT-
PDase on the vasculature, NTPDase 1/CD39, exhibits a tissue distribution
(e.g., endothelium and smooth muscle cells) that coincides with the distri-
bution of several P2X and P2Y receptors. Therefore, vascular hemodynamics
may be tightly regulated by NTPDase 1/CD39 activity. As in knockout mice,
deletion of NTPDase 1/CD39 should favor accumulation of nucleotides and
therefore enhance purinergic signaling. In contrast, we found the opposite
in HCC strips from impotent men with endothelial dysfunction, which ex-
hibit decreased NTPDase 1/CD39 activity. Indeed, we found that vascular
responses of HCC from men with vasculogenic ED to exogenously applied
stable ATP analogues, α,β-MeATP and ATPγ S, were markedly depressed as
compared to control individuals. Similar results were obtained in thrombo-
genesis, angiogenesis and immune cell models, confirming that impairment
of NTPDase 1/CD39 activity leads to P2-purinoceptor desensitization.[10−13]
Thus, purinoceptor desensitization as a result of NTPDase 1/CD39 inacti-
vation appears to be a general phenomenon with potential clinical signifi-
cance under conditions of inflammation or oxidative stress, thereby causing
profound shifts in vascular hemodynamics (see, e.g., Robson et al.[9]).
Not only was the α,β-MeATP-sensitive (which distinguishes P2X1 and
P2X3 receptors from other homomeric forms) contractile response reduced
in HCC strips from vasculogenic impotent men, but also the relaxant effect
of ATPγ S mediated by P2Y receptors was blunted as compared with control
individuals. The P2X1receptor seems to be the predominant P2X receptor
expressed in vascular smooth muscle cells.[14] Although the P2X receptor
profile of endothelial cells is less well characterized and there is evidence for
regional variation in endothelial P2X receptor expression throughout the
vasculature,[15] the predominant receptor on this cell type is probably the
P2X1 receptor.[16] The P2X1 receptor undergoes rapid desensitization,[17]
but recovery from desensitization is extremely slow.[18] Nanomolar ATP con-
centrations drive significant fractions of the rapidly desensitized P2X1 re-
ceptor pool into a long lasting refractory state.[19] Therefore, attenuation of
contractile responses of HCC strips from vasculogenic ED patients to α,β-
MeATP is most likely due to PPADS-sensitive P2X1 desensitization. Since
ATP concentrations can reach ∼1–20 µM in the absence of cell lysis and
persistent elevated levels of the nucleotide can lead to cell toxicity, P2X1
receptor desensitization may actually be a protective phenomenon.
On the other hand, P2Y receptors do not readily desensitize. Instead,
as with other G protein-coupled receptors, desensitization of P2Y recep-
tors may have a slower kinetics involving receptor phosphorylation by pro-
tein kinases and/or uncoupling from the associated G protein. Homolo-
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gous desensitization of IP3 formation by P2Y1- and P2Y2-like receptors was
observed in cultured bovine aortic endothelial cells[20] as well as in rab-
bit mesenteric arterial smooth muscle.[17] Thus, persistent accumulation of
ATP in HCC from men with vasculogenic ED due to impairment of NTP-
Dase 1/CD39 activity might disturb purinergic signaling in erectile tissue
also as a consequence of P2Y-purinoceptor desensitization. This might ex-
plain the shift to the right of the concentration-response curve for the re-
laxing effect of ATPγ S. Another possibility is a differential distribution of
relaxant P2Y1/P2Y2 receptor subtypes on vascular endothelium and smooth
muscle cells, which might be unbalanced by endothelial cell dysfunction.
In conclusion, we have demonstrated that HCC from men with vasculo-
genic ED exhibit decreased NTPDase 1/CD39 activity leading to persistent
extracellular ATP accumulation. As a consequence, attenuation of vascular
responses of HCC strips from impotent patients to stable ATP analogues
may be due to P2-purinoceptor desensitization.
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